The Hemoglobin A1c test is a cornerstone of diabetes management, providing a retrospective view of average blood glucose over the preceding eight to twelve weeks. It is invaluable for guiding treatment decisions and assessing long-term glycemic control. However, clinicians must recognize that A1c measurements can be significantly altered by acute medical events, most notably recent surgical procedures or significant trauma. In these settings, reliance on A1c alone may lead to erroneous clinical decisions, potentially masking dangerous hyperglycemia or prompting unnecessary treatment intensification. Understanding the pathophysiological mechanisms that disrupt A1c accuracy in the perioperative and post‑trauma period is essential for safe and effective diabetes care.

Understanding the Hemoglobin A1c Test

The A1c test measures the percentage of hemoglobin that has glucose irreversibly bound to its beta‑chain N‑terminal valine. This glycation process occurs continuously throughout the lifespan of a red blood cell (RBC), which is typically 120 days. Because the rate of glycation is directly proportional to the ambient glucose concentration, the A1c value reflects the integrated mean glucose over the preceding two to three months. The test assumes a constant RBC lifespan of approximately 120 days in patients with normal erythropoiesis and hemolysis. Any condition that modifies RBC turnover—shortening or lengthening survival—will inherently distort the A1c result, making it unreliable as a metric of glycemic control.

The test is standardized and widely validated for most patients with diabetes. The American Diabetes Association (ADA) recommends A1c targets for nonpregnant adults, and it is used both for diagnosis and monitoring. Nevertheless, the test’s validity is contingent on the stability of red cell kinetics. When those kinetics are disrupted, as they often are after surgery or trauma, the A1c cannot be interpreted in the usual fashion.

Why Surgery and Trauma Affect A1c

Major surgical procedures and traumatic injuries provoke a systemic inflammatory response, often accompanied by hemorrhage, fluid shifts, and stress hormone release. These events have direct and indirect consequences on red blood cell physiology that can dramatically bias A1c results. The three primary mechanisms are blood loss and transfusion, inflammation‑driven changes in RBC lifespan, and the transient metabolic effects of the stress response itself.

Blood Loss and Transfusion

Acute or subacute blood loss is common in both surgical settings and major trauma. Hemorrhage reduces the total number of circulating RBCs and triggers compensatory erythropoiesis. Newly produced cells are less glycated because they have been exposed to glucose for a shorter duration. Consequently, a patient who loses 20–30% of their blood volume may transiently exhibit a lower A1c than their true glycemic status indicates, especially if the bleeding occurred in the weeks preceding the test. Additionally, blood transfusions introduce donor RBCs with unknown glycation histories. If a patient receives packed red blood cells, the A1c will reflect the average glucose of the donor(s) and the storage duration rather than the patient’s own glycemic control. This can produce either falsely low or falsely high results, depending on the donor’s glucose levels.

Inflammation and the Stress Response

Surgery and trauma induce a pronounced release of cortisol, catecholamines, and pro‑inflammatory cytokines (e.g., interleukin‑6, tumor necrosis factor‑α). These mediators promote insulin resistance and stimulate hepatic gluconeogenesis, leading to hyperglycemia—even in patients without prior diabetes. This “stress hyperglycemia” is transient and may not be captured by a test that averages glucose over months. Conversely, the inflammatory milieu can accelerate RBC destruction via increased oxidative stress and membrane damage, thereby shortening RBC lifespan and lowering the A1c despite actual hyperglycemia. The net effect is often a paradoxical dissociation between A1c and concurrent glucose levels.

Altered Red Blood Cell Lifespan

In addition to hemolysis from inflammation, conditions such as postoperative anemia or trauma‑induced splenic sequestration can alter the average age of circulating RBCs. Erythropoietin levels rise to compensate for blood loss, leading to a younger RBC population with less glycosylation. Even without overt hemolysis, a shift toward younger cells will produce a lower A1c. Conversely, if the trauma involves burns or extensive tissue damage, prolonged immobility or chronic inflammation can suppress erythropoiesis, allowing older, more glycated cells to persist, thereby inflating the A1c. The direction of the bias depends on the balance between RBC production and destruction.

Mechanisms Leading to Falsely Low or High A1c

While the mechanisms outlined above influence A1c directionality, it is useful to summarize the specific clinical scenarios that yield each pattern.

Falsely Low A1c

Falsely low A1c results occur when the average age of circulating RBCs is decreased relative to normal. Common causes in the surgical/trauma population include:

  • Acute blood loss: A recent bleed (e.g., gastrointestinal, surgical) that is replaced by reticulocytosis produces a young RBC population.
  • Hemolytic anemias: Drug‑induced or post‑transfusion hemolysis, as well as autoimmune hemolysis triggered by surgery, shorten RBC survival.
  • Iron deficiency anemia recovery: After surgery, patients may receive iron supplements, leading to rapid hemoglobin synthesis and a shift toward younger cells.
  • Erythropoietin therapy: Used to treat postoperative anemia, this directly stimulates marrow output of new RBCs.

In each case, the A1c may be substantially lower than the mean glucose determined by frequent monitor readings or continuous glucose monitoring. For example, a patient with a hemoglobin of 8 g/dL after hip replacement may have an A1c of 6.0% while their average blood glucose over the same period is 180 mg/dL—a clinically significant discrepancy.

Falsely High A1c

Falsely elevated A1c can occur when RBC lifespan is prolonged or when older cells accumulate. Post‑surgery scenarios include:

  • Iron overload: Multiple transfusions can lead to secondary hemosiderosis, which may impair marrow function and extend RBC lifespan.
  • Chronic kidney disease (CKD) exacerbation: Surgery may worsen kidney function, increasing carbamylated hemoglobin (which can interfere with some A1c assays).
  • Hyperbilirubinemia or high triglycerides: Hepatic dysfunction after major abdominal surgery can increase lipemia or bilirubin, leading to assay interference in certain methods.
  • Transfusion of older stored blood: Donor cells that have been stored for extended periods may have accumulated glucose adducts during storage, falsely raising the measured A1c.

Furthermore, conditions that cause slow RBC turnover (e.g., aplastic crisis) are rare but can be triggered by severe illness post‑trauma. The clinician must be alert to any unusual A1c values that are inconsistent with point‑of‑care glucose measurements.

Clinical Scenarios and Case Example

To illustrate the practical impact, consider a 65‑year‑old man with type 2 diabetes undergoing elective coronary artery bypass grafting. He had a preoperative A1c of 7.5% (good control). During surgery, he lost approximately 800 mL of blood and received two units of packed red blood cells. Postoperatively, his point‑of‑care glucose averages over the next week are 200–250 mg/dL due to stress hyperglycemia. However, his A1c drawn one month later is 6.8%—a drop that would suggest improvement. In reality, the lower A1c reflects the combination of blood loss, transfusion of cells with lower glycation, and the presence of young reticulocytes. If the clinician were to de‑intensify therapy based on the A1c, the patient’s glucose could remain dangerously high, increasing the risk of surgical site infection and poor wound healing.

Another scenario involves a trauma patient with multiple rib fractures and a splenic laceration managed non‑operatively. He develops acute blood loss anemia and receives two units of blood. His A1c at hospital discharge is 5.9%, yet his fasting glucose is 160 mg/dL and his random glucose peaks at 280 mg/dL. The false reassurance of a “normal” A1c may delay appropriate initiation of insulin therapy, putting the patient at risk for hyperglycemic complications.

Alternative Monitoring Strategies

Given the unreliability of A1c in the perioperative and post‑trauma period, clinicians must employ alternative or adjunctive methods to assess glycemic control. The choice depends on the clinical question: Are we trying to evaluate short‑term stability after discharge, or do we need a longer‑term measure once the acute phase has resolved?

Fructosamine

Fructosamine measures glycated serum proteins, primarily albumin. Because albumin has a half‑life of approximately 14–20 days, fructosamine reflects glycemic control over the preceding two to three weeks. This makes it ideal for assessing the period immediately after surgery or trauma, when A1c is unreliable. Fructosamine is not affected by RBC lifespan, and it can be measured with a simple blood test. However, it is influenced by low albumin levels (common in critical illness) and by conditions like nephrotic syndrome. Despite these limitations, many experts recommend fructosamine as the preferred short‑term alternative when A1c is invalid. The ADA acknowledges fructosamine as an alternative in certain conditions (ADA Clinical Guide).

Glycated Albumin

Glycated albumin is a more specific measure of albumin glycation, providing a similar timeframe (2–3 weeks). It is less affected by albumin concentration than fructosamine and may be more accurate in patients with protein‑losing states. While not as widely used in the United States, it is available in many clinical laboratories. Studies have shown good correlation with short‑term glucose control in patients with chronic kidney disease and other conditions that distort A1c (Ang et al., Diabetes Care 2019).

Continuous Glucose Monitoring (CGM)

Real‑time CGM systems (e.g., Dexcom G6, Abbott Freestyle Libre) provide glucose readings every 1–15 minutes. They offer a detailed picture of glucose excursions, including postprandial spikes, nocturnal hypoglycemia, and the effects of stress hyperglycemia. For hospitalized patients, CGM is increasingly used in step‑down units, and it can generate metrics such as time‑in‑range (TIR). TIR (percentage of time glucose is 70–180 mg/dL) has been proposed as a surrogate for A1c. Indeed, the ADA now recommends TIR targets for many patients. In the post‑surgical setting, CGM can reveal the true glycemic burden independent of RBC abnormalities. Insurance coverage for outpatient CGM has expanded, making it a practical tool for patients who have recently undergone surgery.

Frequent Self‑Monitoring of Blood Glucose (SMBG)

For patients who do not have access to CGM or fructosamine testing, frequent fingerstick glucose measurements (four to six times daily) remain a reliable way to track glucose control. The clinician can review logbook data or downloads to assess average glucose and patterns. The estimated average glucose (eAG) can be calculated from SMBG data (e.g., 28.7 × A1c – 46.7), but when A1c is inaccurate, direct glucose averaging is more trustworthy. For example, if a patient has 30 measurments over two weeks with an average of 180 mg/dL, that corresponds to an eA1c of approximately 7.8%, even if the lab A1c is lower.

Combining Methods

In many cases, a combination of fructosamine and CGM provides the most comprehensive assessment. Fructosamine gives an integrated 2‑week snapshot, while CGM reveals daily variability and time in range. Once the acute phase has resolved (usually 6–8 weeks after surgery or trauma), the A1c may again become reliable if the patient’s RBC kinetics have normalized. Clinicians should document the reason for alternative testing and recalculate A1c at a later date to re‑establish a baseline.

Recommendations for Clinicians

Based on the evidence and expert consensus, the following practical recommendations can guide management:

  • Suspect A1c inaccuracy in any patient with recent surgery (within 2 months) or trauma with significant blood loss, transfusion, or inflammatory response.
  • Confirm with concurrent glucose monitoring – compare a current A1c to average SMBG or CGM readings over the same period. A discrepancy of more than 1% (e.g., A1c 6.0% but average glucose 180 mg/dL) warrants alternative testing.
  • Order fructosamine or glycated albumin if short‑term assessment is needed, especially when surgery occurred within the past 3 weeks.
  • Use CGM for patients requiring intensive glycemic management after major surgery, such as those on insulin pumps or with marked stress hyperglycemia.
  • Document the reason for not using A1c in the medical record to avoid confusion during transitions of care.
  • Re‑check A1c after 3–6 months once the patient has fully recovered and RBC turnover has returned to normal.
  • Be aware of assay interference – different laboratories use different A1c methods (HPLC, immunoassay, capillary electrophoresis). Some are more susceptible to interference from hemoglobin variants, carbamylated hemoglobin, or labile fractions. Know your lab’s methodology.

For additional guidance, the American Association of Clinical Chemistry (AACC) and the National Glycohemoglobin Standardization Program (NGSP) maintain updated information on conditions that affect A1c (NGSP: Factors that Interfere with HbA1c Measurement).

Conclusion

The Hemoglobin A1c test, while indispensable for routine diabetes care, loses its reliability in the setting of recent surgical procedures or trauma. Acute changes in red blood cell lifespan, blood loss, transfusion, and the systemic inflammatory response all conspire to produce misleading values—either falsely low or falsely high. Clinicians must remain vigilant and integrate alternative monitoring strategies such as fructosamine, glycated albumin, and continuous glucose monitoring to accurately assess glycemic control. By understanding the underlying pathophysiology and employing a multipronged approach, healthcare providers can prevent therapeutic missteps and improve outcomes for patients recovering from these challenging events. As research continues to refine our understanding, the wise clinician will view the A1c not as an infallible number, but as one piece of a complex puzzle that must be interpreted in the context of the patient’s clinical state.

Disclosure: The author has no conflicts of interest. This article is for educational purposes and does not replace clinical judgment.